AARD Quote, Financials, Valuation and Earnings

Immunic, Inc. has a net margin of -- compared to Aardvark Therapeutics, Inc.'s net margin of --. Aardvark Therapeutics, Inc.'s return on equity of -43.34% beat Immunic, Inc.'s return on equity of -521.65%.

Aardvark Therapeutics, Inc. has a consensus price target of $32.70, signalling upside risk potential of 149.14%. On the other hand Immunic, Inc. has an analysts' consensus of $5.38 which suggests that it could grow by 907.12%. Given that Immunic, Inc. has higher upside potential than Aardvark Therapeutics, Inc., analysts believe Immunic, Inc. is more attractive than Aardvark Therapeutics, Inc..

Aardvark Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Immunic, Inc. has a beta of 1.545, suggesting its more volatile than the S&P 500 by 54.491%.

Aardvark Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immunic, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aardvark Therapeutics, Inc. pays -- of its earnings as a dividend. Immunic, Inc. pays out -- of its earnings as a dividend.

Aardvark Therapeutics, Inc. quarterly revenues are --, which are smaller than Immunic, Inc. quarterly revenues of --. Aardvark Therapeutics, Inc.'s net income of -$16.3M is higher than Immunic, Inc.'s net income of -$25.6M. Notably, Aardvark Therapeutics, Inc.'s price-to-earnings ratio is -- while Immunic, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics, Inc. is -- versus -- for Immunic, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of -- compared to Aardvark Therapeutics, Inc.'s net margin of -259.95%. Aardvark Therapeutics, Inc.'s return on equity of -43.34% beat Insmed, Inc.'s return on equity of -193.23%.

Aardvark Therapeutics, Inc. has a consensus price target of $32.70, signalling upside risk potential of 149.14%. On the other hand Insmed, Inc. has an analysts' consensus of $214.78 which suggests that it could grow by 23.5%. Given that Aardvark Therapeutics, Inc. has higher upside potential than Insmed, Inc., analysts believe Aardvark Therapeutics, Inc. is more attractive than Insmed, Inc..

Aardvark Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.085, suggesting its more volatile than the S&P 500 by 8.523%.

Aardvark Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aardvark Therapeutics, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Aardvark Therapeutics, Inc. quarterly revenues are --, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Aardvark Therapeutics, Inc.'s net income of -$16.3M is higher than Insmed, Inc.'s net income of -$370M. Notably, Aardvark Therapeutics, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics, Inc. is -- versus 74.06x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals, Inc. has a net margin of -- compared to Aardvark Therapeutics, Inc.'s net margin of -103.13%. Aardvark Therapeutics, Inc.'s return on equity of -43.34% beat Rhythm Pharmaceuticals, Inc.'s return on equity of -509.34%.

Aardvark Therapeutics, Inc. has a consensus price target of $32.70, signalling upside risk potential of 149.14%. On the other hand Rhythm Pharmaceuticals, Inc. has an analysts' consensus of $139.00 which suggests that it could grow by 29.86%. Given that Aardvark Therapeutics, Inc. has higher upside potential than Rhythm Pharmaceuticals, Inc., analysts believe Aardvark Therapeutics, Inc. is more attractive than Rhythm Pharmaceuticals, Inc..

Aardvark Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals, Inc. has a beta of 2.003, suggesting its more volatile than the S&P 500 by 100.257%.

Aardvark Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aardvark Therapeutics, Inc. pays -- of its earnings as a dividend. Rhythm Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Aardvark Therapeutics, Inc. quarterly revenues are --, which are smaller than Rhythm Pharmaceuticals, Inc. quarterly revenues of $51.3M. Aardvark Therapeutics, Inc.'s net income of -$16.3M is higher than Rhythm Pharmaceuticals, Inc.'s net income of -$52.9M. Notably, Aardvark Therapeutics, Inc.'s price-to-earnings ratio is -- while Rhythm Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics, Inc. is -- versus 39.08x for Rhythm Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Soleno Therapeutics, Inc. has a net margin of -- compared to Aardvark Therapeutics, Inc.'s net margin of 39.4%. Aardvark Therapeutics, Inc.'s return on equity of -43.34% beat Soleno Therapeutics, Inc.'s return on equity of -26.56%.

Aardvark Therapeutics, Inc. has a consensus price target of $32.70, signalling upside risk potential of 149.14%. On the other hand Soleno Therapeutics, Inc. has an analysts' consensus of $113.54 which suggests that it could grow by 145.22%. Given that Aardvark Therapeutics, Inc. has higher upside potential than Soleno Therapeutics, Inc., analysts believe Aardvark Therapeutics, Inc. is more attractive than Soleno Therapeutics, Inc..

Aardvark Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Soleno Therapeutics, Inc. has a beta of -3.123, suggesting its less volatile than the S&P 500 by 412.272%.

Aardvark Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Soleno Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aardvark Therapeutics, Inc. pays -- of its earnings as a dividend. Soleno Therapeutics, Inc. pays out -- of its earnings as a dividend.

Aardvark Therapeutics, Inc. quarterly revenues are --, which are smaller than Soleno Therapeutics, Inc. quarterly revenues of $66M. Aardvark Therapeutics, Inc.'s net income of -$16.3M is lower than Soleno Therapeutics, Inc.'s net income of $26M. Notably, Aardvark Therapeutics, Inc.'s price-to-earnings ratio is -- while Soleno Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics, Inc. is -- versus 22.93x for Soleno Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.